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Abstract
Object
Despite many efforts at reduction, cerebrospinal fluid (CSF) shunt infections are a major
cause of morbidity in shunt surgery, occurring in 5–15% of cases. To attempt to reduce the
shunt infection rate at our institution, we added topical vancomycin (intrashunt and perish-
unt) to our existing shunt infection prevention protocol in 2012.
Methods
We performed a retrospective cohort study comparing all shunted patients in January 2010
to December 2011 without vancomycin (control group, 263 procedures) to all patients who
underwent shunt surgery between April 2012 and December 2015 with vancomycin (inter-
vention group, 499 procedures).
Results
The overall shunt infection rate significantly decreased from 6.8% (control group) to 3.0%
(intervention group) (p = 0.023, absolute risk reduction 3.8%, relative risk reduction 56%). Mul-
tivariate logistic regression analysis confirmed that the addition of topical vancomycin showed
that cases treated under a protocol of topical vancomycin were associated with a decreased
shunt infection rate (odds ratio [OR] 0.49 95% CI 0.25–0.998; p = 0.049). Age < 1 year was
associated with an increased risk of infection (OR) 4.41, 95% CI 2,10–9,26; p = 0.001). Time
from surgery to infection was significantly prolonged in the intervention group (p = 0.001).
Conclusion
Adding intraoperative vancomycin to a shunt infection prevention protocol significantly
reduces CSF shunt infection rate.
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Introduction
The treatment of hydrocephalus consists of inserting a cerebrospinal fluid (CSF) shunt to the
peritoneal or pleural cavities or to the atrium of the heart in the majority of cases. This inser-
tion of foreign body materials may be accompanied by many potential problems, of which
shunt infection is a major one. The average shunt shunt infection rate is about 5–15%,
although lower and higher rates are reported [1–8]. Shunt infections are largely due to skin
flora colonization of the shunt device at surgery, as 90% of infections are caused by Staphylo-
coccus species, and most infections occur within the first few months after surgery [9]. The
impact of a shunt infection is very high. An infection usually leads to shunt explantation and
subsequent re-insertion of a new shunt, leading to prolonged hospitalization of weeks, which
is accompanied by very high extra costs, and most importantly, it may have deleterious neuro-
logical effects.
Many efforts have been taken to reduce the shunt infection rate. Preoperative intravenous
(iv) prophylactic antibiotics are administered routinely and this is a mainstay of prevention
[10]. Many different measures appear to contribute to reducing the shunt infection rate,
although evidence for each separate measure is minimal or nonexistent [11]. Combining of all
these measures into an institutional shunt infection prevention protocol is the most effective
means of preventing shunt infections [5]. The latest development is the use of antibiotic-
impregnated catheters (AIC), with the prolonged release of two different antibiotics. Several
meta-analyses have shown that AIC significantly reduce the shunt infection rate [6, 9, 12–14].
The use of AIC comes with significant extra costs and there are some concerns that it may
increase the development of antibiotic resistance.
After its introduction in 2004, the use of a shunt infection protocol reduced the shunt infec-
tion rate in our department from 12% to 8% in our pediatric patient cohort. To further
decrease the shunt infection rate and motivated by the results of Ragel et al., who used intra-
thecal antibiotics during surgery [15], we added a single new component to our existing proto-
col. A vancomycin solution of 2 mg/ml was used to drench, flush, and fill catheters, reservoirs,
and valves during shunt surgery from April 2012 onwards. This study was performed to evalu-
ate the effect of the addition of vancomycin to the existing protocol on the shunt infection rate.
In addition we assesses (differences in) the time to infection and etiology.
Methods
The work described has been carried out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments involving humans. The study
has been approved by the institutional review board CMO Arnhem—Nijmegen (IRB). The
IRB waived informed consent due to the nature of the investigations.
This was a retrospective cohort study of all consecutive patients receiving any type of CSF
shunt, first implantation, or shunt revision, from January 1, 2010, until 31 December 31, 2011,
and from April 1, 2012, until December 31, 2015. This included patients with previous shunt
infections and complicated shunt surgery. CSF reservoirs, stents, and external CSF drains were
excluded. All patients underwent surgery at the Radboud University Medical Center depart-
ment of neurosurgery.
Two cohorts containing consecutive cases were selected. The first (control group) was a
consecutive series of all patients treated in 2010 and 2011 according to the institutional shunt
infection prevention protocol introduced in 2004 and updated in 2008. In January 2012, van-
comycin was introduced as an add-on to the existing protocol in a test phase for patients
treated only by the first author (EJvL). From April 1, 2012, onwards, vancomycin was included
as part of the new protocol for all patients. All patients receiving a shunt or a shunt revision
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between January 1 and 31 March 31, 2012, i.e., during the try-out phase, were therefore
excluded. The second cohort (intervention group) therefore contained all patients treated
between April 1, 2012, and December 31, 2015, and who received vancomycin in the new
protocol.
Although the protocol is very strict, protocol violations could not be excluded, as protocol
compliance checks were not performed.
A shunt was considered infected if the patient showed clinical signs of wound infection,
septicemia in patients with ventriculoatrial (VA) shunts, peritonitis in patients with ventricu-
loperitoneal (VP) shunts, or meningitis, and if bacteria were cultivated from the blood, perito-
neum, CSF, or the shunt system. A negative culture with typical positive clinical signs and CSF
pleocytosis suggesting infection was also considered a shunt infection. Only shunt infections
within 6 months after surgery (compliant with most of the literature) were collected;
infections < 30 days after surgery were considered early infections.
Shunt infection protocol and vancomycin
Our department has used a strict CSF shunt protocol since 2004, which was updated in 2008.
Table 1 summarizes this protocol. Although the measures are strict, we do not have a protocol
compliance checklist. Protocol violations did occur initially, but updates to the protocol and
crew resource management training have minimized this.
The use of intraoperative vancomycin was added to the above infection prevention mea-
sures in April 2012. Vancomycin was selected because intraoperative contamination by skin
bacteria is the main route of transmission in shunt infection. Vancomycin (500 mg) is added
to 250 ml 0.9% NaCl to create a solution of 2 mg/ml vancomycin. The solution is used to wet
operative gauze, drench and flush the shunt (outside of the patient) and fill the shunt reservoir,
flush the surgical wound superficially, and to wet surgical gloves. Vancomycin is normally not
flushed into the ventricles or spinal thecal sac. The chosen concentration of vancomycin pre-
vents overdosing in even the youngest children.
Data collection and statistical analysis
The data of children aged <17 years were retrieved from a prospective database of compli-
cation registrations in pediatric neurosurgery that was started in our department in 2004.
The data on patients aged >16 years were retrospectively collected from a digital surgical
procedure registration system and digital patient files. All data were collected in an Excel
database.
Statistical analysis was carried out using two-sided Fisher’s exact test and chi-square test for
categorical outcomes. The primary outcome, differences in shunt infection rate before and
after the addition of topical vancomycin, was assessed with logistic regression analysis with
infection within 6 months as dependent variable. Patient factors showing an association with
infection in univariate analysis at a significance level of p<0.1 were included in the multivari-
ate model.
To study the effect of addition of vancomycin to the protocol on the time of infection, we
carried out a multivariable cox proportional hazards regression to compare the time to infec-
tion using the same factors as in the multivariate logistic regression analysis.
Analysis was performed using commercially available statistical software (IBM SPSS Statis-
tics for Windows, Version 22.0, IBM Corp: Armonk, NY). A p-value less than 0.05 was consid-
ered statistically significant.
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Results
Patient population
In the first cohort of patients from 2010–2011 (control group), we studied 263 procedures, of
which 131 were performed in children (<17 years) (Table 2). In children, the male-to-female
(M/F) ratio was 1.08; that of adults was 0.65. The average age of pediatric patients was 6.1 (±
5.5) years; that of adults was 45 (± 20) years. The ratio of first shunt versus shunt revision was
0.54 and 1.13 in children and in adults, respectively, which reflects a much higher revision rate
in children versus adults. A total of 37 procedures were performed in premature neonates (ges-
tational age<36 weeks), 21 of which in the intervention group. Of the 263 procedures in the
control group, 116 were new shunts and 147 shunt revisions. This was in the intervention
Table 1. Radboud University Medical Center shunt infection prevention protocol, version 2012.
OR planning 1. Neonates/infants before older patients
2. Single-bed patient rooms
OR room 1. Minimize number of staff in OR
2. All potential material/implants in OR
3. Closed doors from incision until wound closure
4. OR door sign: “Keep out–shunt surgery”
Patient
preparation
1. Iodine shampoo twice before surgery
2. Regular pillow cleaning before and after surgery
3. Cefazolin 30 minutes before surgery: children 25mg/kg, adults 2g
4. Haircutting only with electric razor; in babies with shaving razor
5. Skin disinfection by surgeon
6. Use of iodine-impregnated skin drape (unless allergic to iodine)
7. Shield from anesthesiological setup by drapes
8. Maintain continuity between sterile draping and surgical instrumentation tables
9. Create a gutter of drapes around patient, preventing instruments sliding from
patient
10. Bowl containing 250 ml 0.9% NaCl + 500 mg vancomycin on table
11. Immerse implants and gauze before use in bowl
Operative
procedure
1. Experienced neurosurgeon or resident under strict supervision
2. Keep surgical time as short as possible
3. Double gloving from the start
4. First perform all skin incisions, dissection, and burr hole before unpacking
implants, minimizing air exposure of implants
5. Remove outer gloves before unpacking implants
6. Unpacked implants immersed directly in vancomycin solution, assembled if
necessary, and immediately implanted into the patient
7. Flush a new shunt piece, do not test extensively
8. Touch implants as little as possible with gloves, rather use instruments
9. Cover open wounds with drenched gauze (vancomycin solution) as much as
possible
10. Careful hemostasis
11. Careful wound closure, prevent necrosis
Postoperative 1. Adequate positioning, avoid local wound pressure (especially in babies and
infants)
2. Do not change bandages first 24 hours after surgery; shower after 72 hours
https://doi.org/10.1371/journal.pone.0190249.t001
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group 222 and 277, respectively. Of all procedures 246 were performed by residents and 516
by neurosurgical staff members with an equal distribution in both study cohorts.
The second cohort (intervention group) comprised 499 procedures, of which 195 were in
children. The M/F ratio of this group was 1.41 and 0.67 in children and in adults, respectively;
the average age was 6.4 (± 5.5) and 49.4 (± 21.1) in children and in adults, respectively. The
first shunt versus shunt revision ratio in children and adults was 0.51 and 1.05, respectively.
No complications attributable to the use of vancomycin were encountered in group 2.
Infection rates overall
Overall, 33 shunt infections occurred in 762 procedures within 6 months after surgery (4,3%)
(Table 2). The infection rate was 13.1% in children1 year, 3.0% in children 1–17 years and
3.0% if17 years. The difference of infection rates between1 year and>1 year of age is sig-
nificant (p = 0.001). Male patients had a higher shunt infection rate than females (5.6% versus
3.2%) but not significant (p = 0.11). Staff neurosurgeons had a higher infection rate than resi-
dents (4.8% vs. 3.3%, ns: p = 0.35). The etiology of hydrocephalus was studied for 10 different
categories with infection rates of 0% to 6.5% but none was identified as a significant risk factor
Table 2. Patient population and infection rates.
Procedures Infections P-value
No. % No. %
Total 762 33 4.3
Gender male 356 46.7 20 5.6
female 406 53.3 13 3.2 ns
Age <1 year 99 13.0 13 13.1 0.000
1–17 years 230 30.2 7 3.0
>17 years 433 56.8 13 3.0
Prematurity yes 37 37.4 6 16.2
no 62 62.6 7 11.3 ns
Protocol control group 263 34.5 18 6.8
Intervention group 499 65.5 15 3.0 0.023
Surgeon staff 516 67.7 25 4.8
resident 246 32.3 8 3.3 ns
Previous surgery <30 days yes 132 17.3 10 7.6
no 630 82.7 23 3.7 0.057
Type of surgery new shunt 338 44.4 11 3.3
revision 424 55.6 22 5.2 ns
Etiology aqueductal stenosis 15 2.0 0 0
congenital 92 12.1 5 5.4
dysrafia 113 14.8 6 5.3
IIH 74 9.7 0 0
NPH 72 9.4 0 0
miscellaneous 43 5.6 1 2.3
posthemorrhgaic 201 26.4 13 6.5
postinfectious 26 3.4 1 3.8
posttraumatic 17 2.2 1 5.9
tumor 109 14.3 6 5.5 ns
P: chi square test, ns = not significant, IIH = idiopathic intracranial hypertension; NPH = normal pressure hydrocephalus
https://doi.org/10.1371/journal.pone.0190249.t002
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(Table 2). Although prematurity led to an infection rate of 16.2%, this was not significantly
higher than in other children <1 year (11.3%, p = 0.545).
Shunt revision surgery came with a higher infection rate than new shunt insertion, but not
significantly (5.2% vs. 3.3%, p = 0.214). However, when we look at shunt revisions we see that
patients with surgery within a 7-day period before (8.9%) or within 30 days before (7.6%) the
actual procedure, had higher infection rates than those with previous surgery> 1 month or
>3 months before (resp. 4.0% and 2.8%). Previous surgery < 30 days shows a relatively strong
association with an increased risk (7.6% versus 3.7%, p = 0.057).
Infection rates in different study cohorts
In the control group, 18 shunt infections occurred (6.8%). In children, the shunt infection rate
was 7.6% versus that of 6.1% in adults. Comparing patients aged <1 year versus >1 year, the
shunt infection rate was 17.0% versus 4.6%. In the intervention group, there were a total of
15 shunt infections (3.0%). The shunt infection rate reduction of 6.8% to 3.0% was statistically
significant (p = 0.023, absolute risk reduction 3.8%, relative risk reduction 56%). The shunt
infection rate of children in the intervention group was 5.1% and in adults 1.6%. The shunt
infection rate in patients aged<1 year to>1 year was 9.6% and 2.2%.
Although the overall reduction of shunt infection rate was significant, there was a remark-
able change over time in the intervention group. During 2012 and 2013, the intervention
group shunt infection rate was 5.6%, and 2014 and 2015 this was reduced to 1.1% (p = 0.006).
Protocol compliance, however, was not a measured variable, while no protocol or institutional
changes have been observed in this study period.
The shunt infection rate of new shunt implantations and shunt revisions in the control
group was 5.2% and 8.2%, respectively; that in the intervention group was 2.3% (p = 0.197)
and 3.6% (p = 0.063), respectively. Of the 30 patients with a shunt infection, 3 had a reinfection
at new shunt insertion, which renders a re-infection rate of 10% after previous shunt infection.
This is not significantly different from the overall cohort (p = 0.14). All 3 reinfections occurred
in the control group, but the difference to the intervention group without reinfections was not
significant (p = 0.22).
Risk factors for shunt infection
Only factors that had a relative association (p<0.1) with shunt infection in univariate analysis
(Table 3) were included for multivariate analysis. Prematurity, sex, previous shunt infection,
type of surgeon and etiology were thus excluded as risk factors. Multivariate analysis demon-
strated that only an age of the patient <1 year (OR 4.41; 95% CI 2.10–9.26) was a risk factor
Table 3. Multivariate logistic regression analysis of risk factors for shunt infection.
Risk factors No. of cases Univariate analysis Multivariate analysis
OR 95% CI OR 95% CI
Gender (female) 406 0.56 0.27–1.13
Age <1 year 99 4.86 2.33–10.12 4.41 2.10–9.26
Prematurity (cases <1 year) 37 1.52 0.47–4.93
New protocol 499 0.42 0.21–0.85 0.49 0.24–0.998
New shunt 338 0.62 0.29–1.29
Surgeon (staff) 516 1.52 0.67–3.41
Previous surgery (<1month) 132 2.16 1.00–4.66 1.84 0.83–4.07
https://doi.org/10.1371/journal.pone.0190249.t003
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for infection and that our new protocol with vancomycin (OR 0.49; 95% CI 0.24–0.998) was a
protective factor.
Time to infection
Overall, 23 shunt infections (70%) occurred early, within 30 days after surgery. In the control
group (without topical vancomycin), 17 of 18 infections (94%) occurred within 1 month; in
the intervention group, only 6 of 15 infections (40%) were early (p = 0.001). Median time to
infection was 7 days (2–33) versus 38 (4–105) days. Cox proportional hazard regression analy-
sis showed a hazard ratio (HR) of 0,47 (95% CI 0.24–0.93, p = 0.031) for the intervention
group versus the control group, a HR of 4,38 (95% CI 2,17–8,84, p = 0,001) for age<1year and
a HR of 1,86 (95% CI 0,88–3,96, p = 0,11) for previous surgery within 1 month.
Microbiology
Table 4 lists the causative microorganisms found in the cultures, both for initial shunt place-
ments and for revision surgery. No microorganisms were found in only two cases, although
the clinical presentation and CSF clearly showed shunt infection. Thirteen infections (42% of
known organisms) were caused by different species of coagulase-negative staphylococci
(CoNS), and 7 times by S. aureus (23%). Although the numbers were low, they do not seem to
show alterations in the spectrum of causative organisms after the introduction of vancomycin.
The minimum inhibitory concentration (MIC) of vancomycin was determined for 10 out
of 14 microorganisms in the intervention group. The MIC varied from 0,5–2 μg/ml and no
vancomycin resistant strains were identified.
Discussion
We studied the effect of adding topical vancomycin to a previously implemented shunt infec-
tion prevention protocol on the incidence of postoperative shunt infections. The shunt infec-
tion rate decreased significantly from 6.8% pre-implementation to 3.0% post-implementation
and remained significant after correction for confounders in multivariate logistic regression
analysis. The reduction was greater in adults than in children and decreased further during the
study period to<2%; thus, shunt infections have become a marginal problem.
Although we did not monitor protocol violations, we discovered based on samples that the
use of vancomycin was occasionally forgotten, especially in the first year. Efforts were made to
increase protocol awareness and adherence in that time, especially in scrub nurses, who are the
mainstay in executing the use of vancomycin. Repetitively emailing the neurosurgical staff and
residents with reminders and the provision of motivational speeches to all contributing nurs-
ing staff subsequently made the new protocol a joint effort and joint responsibility, which may
Table 4. Pathogen identified at shunt infection.
Control Group Intervention Group
Microorganism No. Microorganism No.
Coagulase-negative staphylococci 7 Coagulase-negative staphylococci 6
Staphylococcus aureus 4 Staphylococcus aureus 3
Streptococcus viridans 1 Streptococcus mitis 1
Enterobacter cloacae 2 Klebsiella oxytoca 1
Pseudomonas aeruginosa 1 Proprionibacterium acnes 2
Escherichia coli 2 Enterococcus faecalis 1
No organism 1 No organism 1
https://doi.org/10.1371/journal.pone.0190249.t004
Topical vancomycin in CSF shunts
PLOS ONE | https://doi.org/10.1371/journal.pone.0190249 January 9, 2018 7 / 13
also have contributed to the improved results over the years. Without a formal compliance reg-
istration this remains, however, speculative.
Our results compare favorably with the results of other studies in which a strict preven-
tion protocol was followed or in which AIC have been used [3–5, 13, 14, 16, 17]. Our study
might be biased by better compliance to the shunt infection prevention protocol as a
whole after the introduction of the protocol. However, the other components of this pro-
tocol had been introduced in 2004 and the shunt infection rate had been stable for many
years before the study intervention, probably mirroring constant compliance. We noted
that in the first half of our study, wound breakdown was a major factor in the development
of shunt infection in infants. In the second half of the study, when our shunt infection rate
dropped from 5.6% to 1.1%, we did not encounter a single wound breakdown or skin lac-
eration. Paying particular attention to the mechanical factors of wound healing may thus
contribute to a lower shunt infection rate. Obviously, this cannot be the explanation for
the observed decrease in shunt infection rate among the adult patients. Only a single fac-
tor being changed in an existing protocol suggests that vancomycin was at least partially
responsible for the observed effect.
Interestingly, the use of vancomycin shifted the occurrence of a shunt infection in time to a
later period, with 60% of infections occurring after 1 month while only 6% of infections
occurred after 1 month without vancomycin, and thus a prolonging of the time-to-infection
due to the use of vancomycin. However, the spectrum of causative microorganisms did not
change as a result of the use of vancomycin and there are no signs that remaining infections
are the result of vancomycin resistant strains of bacteria.
CSF shunt infection prevention
The mainstay of shunt infection prevention is surgery protocolization and preparation. The
first and most impressive proof of the shunt infection rate-lowering effect of such a protocol
was reported by Choux et al., who were able to reduce the shunt infection rate to 1% in a large
cohort of pediatric patients [18]. Hardly anyone has reproduced this result. A main reason for
this is that the strictness of their protocol conflicted with the typical logistics in teaching hospi-
tals. The use this protocol would mean the absolute end of training for new residents, scrub
nurses, anesthesiologists, as they would not be allowed to participate in the OR. Many elements
of the protocol by Choux et al., however, have found their way into the myriad protocols cur-
rently used worldwide, and many hospitals have thus been able to lower their shunt infection
rate.
There is, however, very little or even no hard evidence for each measure in these protocols
separately, and it seems that it is the “package” that is effective [5, 11]. The motto “It is more
important to do the same than to do it right” is relevant to many different medical processes,
be it open heart surgery, treating sepsis in the intensive care unit, or transurethral resection of
the prostate (TURP). Thus, decreasing treatment variation or practicing variation decreases
error rates and costs and improves outcomes [19]. It is most likely this effect that reduces the
shunt infection rate the most.
The North American Hydrocephalus Clinical Research Network (HCRN) further sup-
ports the importance of protocol compliance. It proved that an 11-step protocol signifi-
cantly lowered the shunt infection rate and that protocol compliance was inversely related
to shunt infection rate [5]. In a follow-up study on AIC, in which AIC were added as part of
the standard protocol, the shunt infection rate remained the same [4]. It appears that the
protocol as a package is of more importance than the use of AIC for reducing shunt infec-
tion rate.
Topical vancomycin in CSF shunts
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Only by changing one step of a multistep protocol can one study the effect of a single mea-
sure. We have shown that adding a single step to an existing protocol (topical vancomycin) sig-
nificantly reduced shunt infection rate.
Intravenous and intrathecal antibiotics
A meta-analysis by Klimo et al. showed that the application of iv antibiotics has more or less
become an internationally accepted standard with a moderate degree of clinical certainty that
it lowers the shunt infection rate [10, 20], although the number of antibiotics used varies
widely. There appears to be consensus that iv antibiotics should be given 15–30 minutes prior
to skin incision, but whether antibiotics should be continued for one or more days after sur-
gery is subject to wide practice variation. We use cefazolin, a first-generation cephalosporin,
providing coverage for methicillin-susceptible S. aureus (>95% of S. aureus isolates in The
Netherlands are methicillin-susceptible), and to a lesser extent, for Enterobacteriaceae.
Vancomycin is widely used intrathecally for treating shunt-related infections [21]. How-
ever, it is only sporadically used for preventing infection, both iv and intrathecally. Ragel et al.
initiated the use of both gentamycin and vancomycin intrathecally for preventing infection
and reduced the shunt infection rate from 5.4% to 0.4% [15]. Moussa and Mohamed used a
similar antibiotic regimen in a small, prospective, randomized trial of children aged<1 year,
but applied the antibiotics differently. Gentamycin and vancomycin were injected at the end
of surgery into the ventricular reservoir and through the skin around the shunt hardware
every 5 cm along the hardware, and in one group of patients, repeated after a week. They thus
significantly reduced the shunt infection rate (from 30% to 2.5%) [22].
Although we did not copy these two protocols, the protocol of Ragel et al. was our incentive
for altering our protocol and for introducing vancomycin intrathecally. However, protocol
compliance is difficult to establish when many different surgeons have to adhere to a new pro-
tocol or when the protocol becomes too complicated, e.g., different dosages for children and
adults. Therefore, we attempted to determine a means of applying vancomycin to air-exposed
tissue/wounds and shunt hardware such that overdosing is always prevented even in the youn-
gest babies. We therefore wanted to limit the vancomycin dosage to<10 mg in babies. This
can be accomplished with a solution of 2 mg/ml vancomycin, as vancomycin is not introduced
intrathecally, only inserted inside the shunt (volume of valve and tubing < 2 ml), while vanco-
mycin solution–drenched gauzes come into contact with open wounds but hardly leave any
solution behind after wound closure. After unpacking, the shunt tubing is immediately placed
in the vancomycin solution and therefore only exposed to air for 2 seconds. All handling of the
tubing is subsequently performed with instruments, wetted gloves, and wetted gauzes. In fact,
our application of vancomycin is thus topical in the wound only.
There is no scientific basis for the manner in which we apply vancomycin. Practicality,
safety, and simplicity were our reasons for limiting the use of vancomycin to this protocol.
Our way of applicating vancomycin differs from intrathecal use of vancomycin in that intra-
thecal vancomycin only flushes the inside of the tube system, while topical vancomycin also
flushes the outside of tubes and valves, thus those parts that are exposed to contamination.
Antibiotic-impregnated catheters
Recent studies have investigated another form of topical prophylactic antibiotic application. In
vitro studies have shown that impregnating catheters with antibiotics allow the prolonged
release of antibiotics over weeks, which prevents bacterial colonization of these catheters. Pro-
spective double-blinded multicenter randomized trials have established that AIC for external
ventricular drainage (EVD) significantly reduced catheter infections [23, 24], although one
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such study did not report any difference [17]. Meanwhile, many different but relatively small
studies showed decreased shunt infection rates with the use of AIC. Some of these studies
achieved a statistically significant reduction of shunt infection rates, while others did not.
Meta-analysis of these pooled data by different authors appear to prove that the effect of AIC
is real and significant, although with only a class III level of evidence and level III recommen-
dation [6, 9, 12, 14]. Others have shown that AIC might save lives, prevent infection-related
neurological morbidity, and are also cost-effective [13, 25]. Therefore, AIC use has become
increasingly popular, and some suggest that this should become standard of care.
However, there are some concerns as well. First, there may be the risk of bacterial resistance
developing against the antibiotics used. Thus far, no evidence shows such a development [3],
although the meta-analysis by Konstantelias et al. showed that antimicrobial shunt catheters
were associated with higher risk for methicillin-resistant staphylococcus aureus (MRSA), non-
staphylococcal, and gram-negative bacterial infections, and thus a shift towards more virulent
strains [6]. In 2 studies, however, shunt revision surgery of shunts in which in previous surgery
used, an AIC led to an increased shunt infection rate of 11.7% [3]. The numbers are still too
low to draw definitive conclusions, but follow-up studies in the coming years will shed light on
this concern.
Another concern is the fact that the most impressive decrease of shunt infection rates is
reported in centers with an offset of a relatively high shunt infection rates before changing to
the use of AIC. In a British multi-center trial of 3 academic pediatric neurosurgical institu-
tions, AIC significantly reduced the shunt infection rate overall, but there was no change in
the shunt infection rate after AIC was introduced in one center with an already much lower
shunt infection rate than the other 2 centers [16]. This suggests that there may be bias due to
the use of shunt infection prevention protocol or just due to the increased attention placed
on infection prevention. In most studies, the effect of AIC is compared to a retrospective series
of shunt surgery, so that introducing AIC is part of a new infection prevention protocol or
improved compliance with a previous protocol. A surgeon cannot be blinded to the yellow
AIC when non-AIC are usually white, so there is bias. In at least one European neurosurgical
center in which AIC significantly decreased that institute’s shunt infection rate, the shunt
infection rate remained unchanged after discontinuation of the use of AIC (personal
communication).
The HCRN has shown that adding AIC to an already proven effective 11-step protocol with
strong protocol compliance did not further decrease the shunt infection rate [4].
In light of the above findings, it seems justified to conclude that it has not been established
that AIC significantly decrease shunt infection rate and that a protocol effect on decreasing
shunt infection rate is just as likely. More studies such as that performed by the HCRN, e.g., in
Europe, are urgently needed. As the shunt infection rate-reducing effect of our protocol is of
the same size or even better than that obtained with AIC, our protocol would also warrant the
same international scrutiny through further studies. However, the incremental costs of vanco-
mycin are $10 per surgery versus $400 for AIC, and thus our protocol could be an alternative
to AIC and should be the first choice in developing and third-world countries. Using vanco-
mycin instead of AIC saves our department more than €50,000 annually.
Study limitations
Several limitations regarding our study should be considered. We retrospectively examined 2
consecutive patient cohorts, which may be subject to several types of bias. Changing a protocol
in the second group may have led to protocol bias. However, the best results were obtained
2–3 years after changing the protocol and not immediately after, which was to be expected in
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the case of protocol bias. Also, the results were not monitored by all surgeons, but only by a
single person (EJvL) who is one of the surgeons and thus not an independent investigator.
The primary outcome was shunt infection. Shunt infection leads to surgery or at least pro-
longed hospitalization. Outpatient treatment of a shunt infection does not go unnoticed by the
neurosurgeon. Loss of patient follow-up as a result of treatment elsewhere does not occur in
the landscape of Dutch neurosurgical care; therefore, shunt infections treated at a different
hospital would not have contributed to observation bias. Missing or unregistered diagnoses of
shunt infections are therefore unlikely to cause bias.
Although the new updated protocol was introduced uniformly to the neurosurgical staff
and surgical nurses and was rather simple and strict, the compliance rate of protocol adher-
ence is unknown. In a few cases, we found that vancomycin was forgotten during surgery. The
reduction of shunt infection rate over time in group 2 suggests improved protocol compliance.
In their HCRN studies, Kestle et al. showed that adherence to a protocol increases results and
reduces shunt infection rate [5]. We cannot rule out that better adherence to the other aspects
of the protocol instead of the addition of topical vancomycin may be (partially) responsible for
the observed decrease in infection response rate. However, the increased time to infection in
the intervention group offers a biological explanation for the protective effect of vancomycin
rather than better adherence to the other aspects of the protocol.
Conclusions
The use of 2 mg/ml intraoperative topical vancomycin (intrashunt and perishunt) in combina-
tion with a multistep shunt infection prevention protocol significantly reduces the shunt infec-
tion rate for internalized CSF shunts and this treatment may be a cheaper alternative to AIC
use.
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